ARTL
NASDAQArtelo Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.33+0.01 (+0.76%)
02:30 PM07:45 PM
News · 26 weeks630%
2025-12-142026-06-07
Mix4490d
- SEC Filings29(66%)
- Other14(32%)
- Offering1(2%)
Latest news
25 items- PRArtelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development SuccessSOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces that Myles Osborn, Lead Medicinal Chemist at Artelo, is delivering an oral presentation today highlighting encouraging metabolite identification and profiling data from the Company's lead FABP inhibitor candidate, ART26.12, during the 7th RSC-BMCS/DMDG New Perspectives in DMPK and Medicinal Chemistry Conference, held at the Burlington House in London. The presentation fe
- SECSEC Form DEFA14A filed by Artelo Biosciences Inc.DEFA14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form DEF 14A filed by Artelo Biosciences Inc.DEF 14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECArtelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form PRE 14A filed by Artelo Biosciences Inc.PRE 14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form 424B5 filed by Artelo Biosciences Inc.424B5 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form EFFECT filed by Artelo Biosciences Inc.EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form 424B5 filed by Artelo Biosciences Inc.424B5 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECArtelo Biosciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form SCHEDULE 13G filed by Artelo Biosciences Inc.SCHEDULE 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
- SECSEC Form 10-Q filed by Artelo Biosciences Inc.10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial ResultsSOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the quarter ended March 31, 2026, and outlined upcoming milestones across its portfolio. Business Highlights ART26.12 Progressing through Phase 1 studies: Following positive first-in-human Phase 1 single ascending dose and preliminary food-effect data with ART26.12, Artelo continues preparatio
- SECAmendment: SEC Form S-3/A filed by Artelo Biosciences Inc.S-3/A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form S-3 filed by Artelo Biosciences Inc.S-3 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor DevelopmentSOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5 (FABP5) inhibitor platform. ScienceMachine's platform, which leverages cutting-edge AI agent technology, is built to interrogate large biological datasets in a fraction of the time and cost of traditional methods. The partnership is harnessing ScienceMachine'
- PRArtelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class ProfileDemonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year Phase 1 SAD Study Exhibited Excellent Safety with Zero Adverse Events Attributed to ART26.12 SOLANA BEACH, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the publication of a peer‑reviewed article titled "Evaluating fatty acid-binding protein 5 (FABP5) as a therapeutic target for pain management" in the European Journa
- SECSEC Form 424B3 filed by Artelo Biosciences Inc.424B3 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form EFFECT filed by Artelo Biosciences Inc.EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form S-1 filed by Artelo Biosciences Inc.S-1 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECArtelo Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- PRArtelo Biosciences Regains Compliance with Nasdaq Listing RequirementsSOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced that it has received a letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), the "Equity Rule," and Listing Rule 5620(a), the "Annual Shareholders Meeting Rule." Nasdaq further confirmed that, based on the Company's Form 8-K filed January 30, 2026, the Company held its reconvened annual meeting on that date
- SECSEC Form D filed by Artelo Biosciences Inc.D - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECSEC Form SCHEDULE 13G filed by Artelo Biosciences Inc.SCHEDULE 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
- SECSEC Form EFFECT filed by Artelo Biosciences Inc.EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
- SECArtelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
ARTL FAQ
6 questionsWhat does Artelo Biosciences Inc. do?
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for...Where does ARTL stock trade?
Artelo Biosciences Inc. (ARTL) is listed on NASDAQ.What sector and industry is ARTL in?
Artelo Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ARTL?
Artelo Biosciences Inc. has had 2 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $2000.00 price target on 2025-07-08. Recent price targets range from $400.00 to $2000.00.What companies are similar to ARTL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ARTL side-by-side with any of them on Quantisnow.How can I track ARTL on Quantisnow?
Quantisnow aggregates Artelo Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARTL to receive live email and push alerts on every new disclosure.